Multiplicom has announced that it is launching new genomic and somatic mutation detection kits based on its proprietary MASTR technology.
The genomic kits enable PCR amplification of all coding regions of genes known to cause Mucovisidosis, Marfan syndrome, Alport syndrome, Polycystic Kidney Disease, Familial Mediterranean Fever and Duchenne Muscular Dystrophy through the identification of single nucleotide polymorphisms, small deletions/insertions and copy number variations.
The EGFR MASTR kit is Multiplicom’s first somatic mutation detection product for the analysis of tumour tissue, targeting exons 18 to 21 of the EGFR gene, key to selecting the most effective treatment options.
These newly launched tests complement Multiplicom’s MASTR product line which can be used in combination with all benchtop MPS instruments.
Earlier this month, Multiplicom started shipping BRCA MASTR Dx, its first CE/IVD labelled kit, and is in the process of qualifying other kits for EU regulatory approval.
Dr Dirk Pollet, CEO of Multiplicom, said: “The introduction of the new kits establishes Multiplicom as a European leader in the implementation of MPS in routine diagnostic labs. Multiplicom’s products are simple, easy to use, only require standard equipment and are compatible with MPS equipment from Roche, Life Technologies and Illumina.”